Dive Into Dollar Tr...
Health Care: Drugs
Seattle Genetics Inc. (SGEN: NASDAQ)
$36.70 0.38 | 1.05%
05/17/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with SGEN
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ProColumbia Wanger Asset Manag...
- ContributorEarnings Short Squeeze Play...
- UserOwn Now
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Biotech Stocks Loved and...
Latest SGEN Headlines from TheStreet
- 5 Stocks Poised for Breakouts 04.19.13 | 02:04 pm
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX 04.05.13 | 06:04 am
- Declines From Seattle Genetics Inc. (SGEN) Drive Down Health Care Sector 03.28.13 | 05:03 pm
- 4 Stocks Pushing The Drugs Industry Lower 02.13.13 | 12:02 pm
- 5 Stocks Poised to Pop on Bullish Earnings 02.11.13 | 12:02 pm
- Cramer's Top Stock Picks: IMGN ENG SGEN 12.11.12 | 06:12 am
- Cramer's 'Mad Money' Recap: No Deal = No Good 12.10.12 | 08:12 pm
- Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer 12.10.12 | 07:12 am
- Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer 12.08.12 | 10:12 am
Press Releases for SGEN
- Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With ADCETRIS® (Brentuximab Vedotin) In Relapsed Hodgkin Lymphoma And Systemic ALCL - Business Wire 03.18.13 | 09:03 am
- Seattle Genetics To Present At Upcoming Investor Conferences - Business Wire 02.27.13 | 09:02 am
- Seattle Genetics Reports Fourth Quarter And Year 2012 Financial Results - Business Wire 02.12.13 | 04:02 pm
- Seattle Genetics Initiates Two Phase I Trials Of SGN-CD19A - Business Wire 02.06.13 | 09:02 am
- Health Canada Approves ADCETRIS® (Brentuximab Vedotin) For The Treatment Of Relapsed Or Refractory Hodgkin Lymphoma (HL) And Systemic Anaplastic Large Cell Lymphoma (sALCL) - Business Wire 02.01.13 | 02:02 pm
- Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2012 Financial Results On February 12, 2013 - Business Wire 01.29.13 | 09:01 am
- Seattle Genetics Announces Data From ASG-5ME Phase I Clinical Trial For Pancreatic Cancer - Business Wire 01.25.13 | 09:01 am
- Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL) - Business Wire 01.24.13 | 09:01 am
- Seattle Genetics To Present At The J.P. Morgan Healthcare Conference - Business Wire 01.03.13 | 09:01 am
- Seattle Genetics Highlights Data Presentations From Genentech ADC Collaborator Programs At ASH Annual Meeting - Business Wire 12.11.12 | 07:12 am
Partner Headlines for SGEN
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Anything Can Happen This Year For Celldex - Seeking Alpha 02.18.13 | 09:02 am
- Show Me The Money: ADC Revenue Payloads Miss The Mark - Seeking Alpha 11.26.12 | 09:11 am
- UPDATE: Credit Suisse Initiates Seattle Genetics at Outperform; Antubody Pure-Play - Benzinga 11.13.12 | 01:11 pm
- Millennium, Seattle Genetics Announce Phase 3 Clinical Trial of ADCETRIS - Benzinga 11.01.12 | 08:11 am
- Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN - NASDAQ 09.10.12 | 02:09 pm
- WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS - NASDAQ 09.03.12 | 02:09 pm
- Armed Antibodies: The Latest Weapon In The War Against Cancer - Seeking Alpha 07.23.12 | 09:07 am
- Healthcare Biz Recap: Affymax On A ROLL, Acadia CRASHES - Wall St. Cheat Sheet 07.15.12 | 11:07 am
- Mid-Cap Biotech Stocks Accumulated By The World's Largest Money Managers - Seeking Alpha 07.13.12 | 06:07 pm
